a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies

Inclusion Criteria

• •1. CD19-expressing or CD20-expressing relapsed or refractory B cell malignancies after at least one standard chemotherapy and one salvage regimen.According to current traditional therapies, there must be no available alternative curative therapies.
• •2. Patients enrolled must have an evaluated score above 60 with KPS.
• •3. Expected survival time of patients enrolled is over 3 months.
• •4. Gender is not limited, age from 14 years to 75 years.
• •5. Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.
• •6. Adequate absolute CD3 count estimated need to be assured for obtaining target cell dose based on dosage cohorts.
• •9. Ability to give informed consent.
• •10. Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus.
• •11. Cardiac function: Left ventricular ejection fraction greater than or equal to 40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO.
• •12. Renal function: Creatinine level of peripheral blood is required no greater than 133umol/L.
• •14. Patients volunteer to participate in the research.